Alternate Title
Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outcomes
Outline
Trial Contact Information
Related Information
Registry Information

Alternate Title

Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Basic Trial Information

Special Category: NIH Clinical Center trial

Objectives

Primary

1. Compare the event-free survival of patients with previously untreated de novo diffuse large B-cell non-Hodgkin's lymphoma treated with R-CHOP comprising rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone vs EPOCH-R comprising etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab.
2. Determine molecular predictors of outcome (using molecular profiling) in patients treated with these regimens.

Secondary

1. Compare the response rate and overall survival of patients treated with these regimens.
2. Compare the toxicity of these regimens in these patients.
3. Correlate the clinical parameters (i.e., toxicity, response, survival outcomes, and laboratory results) with molecular profiling in patients treated with these regimens.
4. Assess the use of molecular profiling for pathological diagnosis in patients treated with these regimens.
5. Identify new therapeutic targets using molecular profiling.
6. Perform a comprehensive analysis of somatic alterations to the tumor genome in order to understand which genomic alterations are somatically acquired by the tumor and which are encoded in the germ line of the patient.
7. Identify biomarkers of response to chemotherapy by FDG-PET/CT imaging that are predictive of histopathologic remissions and survival in patients with stage I (mediastinal), II, III, or IV untreated DLBCL.
8. Evaluate the use of semiquantitative measurements of FDG uptake in defining FDG-PET/CT-based biomarkers of response to chemotherapy in patients with DLBCL.
9. Determine whether FDG-PET/CT measurements of tumor response after the second cycle of chemotherapy can predict clinical response.
10. Establish a standardized protocol for FDG-PET/CT image acquisition.
11. Determine additional FDG-PET/CT parameters (e.g., the ratio of tumor SUVmax to liver SUVmean; SUVs corrected for body surface area and lean body mass; nuclear medicine physician’s assessment) and evaluate their utility in refining FDG-PET/CT based biomarkers of response to therapy.
12. Evaluate inter-institutional reproducibility of FDG-PET/CT measurements for this indication.

Entry Criteria

Disease Characteristics:

• Histologically confirmed* de novo B-cell non-Hodgkin's lymphoma (NHL) of 1 of the following WHO histologic subtypes:
  • Diffuse large cell lymphoma, including any of the following morphologic variants:
    • Centroblastic
    • Immunoblastic
    • T-cell/histiocyte rich
    • Anaplastic
  • Mediastinal (thymic) large cell lymphoma
  • Intravascular large cell lymphoma

   [Note: *Fine needle aspirates or core biopsies must not be the only diagnostic material]

• Stage I primary mediastinal (thymic) OR stage II-IV disease

• CD20-positive disease

• No underlying low-grade lymphoma (e.g., transformed lymphoma or low-grade lymphoma in the bone marrow)

• No known lymphomatous CNS involvement
  • Lumbar puncture required unless there are no neurological symptoms

 [Note: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology.]

Prior/Concurrent Therapy:

Biologic therapy

• No prior rituximab

Chemotherapy

• No prior chemotherapy for other malignancies
• No prior cytotoxic chemotherapy
• No other concurrent chemotherapy

Endocrine therapy

• Prior short course (< 10 days) glucocorticoids allowed for an urgent local disease complication (e.g., cord compression or superior vena cava syndrome) at diagnosis
• No concurrent hormonal therapy except steroids for adrenal failure or hormones for non-disease related conditions (e.g., insulin for diabetes)
• No concurrent dexamethasone or other steroidal antiemetics

Radiotherapy

• Prior limited field radiotherapy allowed for an urgent local disease complication (e.g., cord compression or superior vena cava syndrome) at diagnosis
• No concurrent radiotherapy except for isolated CNS lesions

Surgery

• Not specified

Other

• No other concurrent investigational or commercial agents or therapies for NHL

Patient Characteristics:

Age

• 18 and over

Performance status

• ECOG 0-2

Life expectancy

• Not specified

Hematopoietic

• Absolute neutrophil count ≥ 1,000/mm^3*
• Platelet count ≥ 100,000/mm^3*
• No active bleeding unrelated to NHL

 [Note: *Unless due to NHL]

Hepatic

• Bilirubin ≤ 2 mg/dL*

 [Note: *Unless due to NHL or Gilbert's disease]

Renal

• Creatinine ≤ 1.5 mg/dL^*

  OR

• Creatinine clearance ≥ 50 mL/min^*

 [Note: *Unless due to NHL]

Cardiovascular

• No active ischemic heart disease
• No congestive heart failure

Other

• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• HIV negative
• No active uncontrolled bacterial or viral infection unrelated to NHL
• No other active medical process unrelated to NHL

Expected Enrollment

A total of 478 patients (239 per treatment arm) will be accrued for this study within 4.5 years.

Outcomes

Event-free survival 5 years after completion of study treatment

R-CHOP and DA-EPOCH-R molecular predictors of outcome as measured by cDNA microarray 5 years after completion of study treatment

Outline

This is a randomized, multicenter study. Patients are stratified according to International Prognostic Index score. Patients are randomized to 1 of 2 treatment arms.

• Arm I (R-CHOP): Patients receive rituximab IV, cyclophosphamide IV, doxorubicin IV over 3-5 minutes, and vincristine IV on day 1 and oral prednisone once daily on days 1-5. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.

• Arm II (EPOCH-R): Patients receive rituximab IV on day 1, doxorubicin IV, etoposide IV, and vincristine IV continuously over 96 hours on days 1-4, cyclophosphamide IV on day 5, and oral prednisone twice daily on days 1-5. Patients also receive filgrastim (G-CSF) once daily on days 2-11 or until blood counts recover. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed every 3 months for 2 years and then every 6 months for up to 3 years.

Trial Contact Information

Trial Lead Organizations

Cancer and Leukemia Group B

Wyndham Wilson, MD, PhD, Protocol chair		Ph: 301-435-2415
Andrew D. Zelenetz, MD, PhD, Protocol co-chair		Ph: 212-639-2656; 800-525-2225

U.S.A.
Alabama
	Anniston
	Regional Medical Center
		Ellen Spremulli	Ph:  256-235-5877
Alaska
	Fairbanks
	Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital
		Craig Nichols, MD	Ph:  503-494-6346
California
	Glendale
	Glendale Memorial Hospital Comprehensive Cancer Center
		Clinical Trials Office - Glendale Memorial Hospital Comprehensive Cancer Center	Ph:  818-409-7653
	La Jolla
	Rebecca and John Moores UCSD Cancer Center
		Clinical Trials Office - Rebecca and John Moores UCSD Cancer Center	Ph:  858-822-5354
			Email: cancercto@ucsd.edu
	Mission Hills
	Providence Holy Cross Cancer Center
		Bahareh Bahadini	Ph:  818-898-4410
	Mountain View
	Camino Medical Group - Treatment Center
		Peter Yu, MD	Ph:  408-524-5814
	Orange
	St. Joseph Hospital Regional Cancer Center - Orange
		Tiberio Lindgren	Ph:  714-771-8999
	Palm Springs
	Desert Regional Medical Center Comprehensive Cancer Center
		Clinical Trials Office - Desert Regional Medical Center Comprehensive Cancer Center	Ph:  760-416-4730
	Palo Alto
	Palo Alto Medical Foundation
		David Leibowitz	Ph:  650-321-4121
	Sacramento
	University of California Davis Cancer Center
		Clinical Trials Office - University of California Davis Cancer Center	Ph:  916-734-3089
	Saint Helena
	Saint Helena Hospital
		Gregory Smith	Ph:  707-963-3611
	San Diego
	Naval Medical Center - San Diego
		Preston Gable, MD, FACP	Ph:  619-532-7319
Colorado
	Aurora
	Aurora Presbyterian Hospital
		Eduardo Pajon, MD	Ph:  303-399-8020ext2261
	Boulder
	Boulder Community Hospital
		Clinical Trials Office - Boulder Community Hospital	Ph:  303-938-5253
	Colorado Springs
	Memorial Hospital Cancer Center - Colorado Springs
		Clinical Trials Office - Memorial Hospital	Ph:  719-365-2406
	Penrose Cancer Center at Penrose Hospital
		Clinical Trials Office - Penrose Cancer Center	Ph:  719-776-5275
	Denver
	CCOP - Colorado Cancer Research Program
		Eduardo Pajon, MD	Ph:  303-399-8020ext2261
	Porter Adventist Hospital
		Eduardo Pajon, MD	Ph:  303-399-8020ext2261
	Presbyterian - St. Luke's Medical Center
		Clinical Trials Office - Presbyterian - St. Luke's Medical Center	Ph:  303-839-6000
	Rose Medical Center
		Eduardo Pajon, MD	Ph:  303-399-8020ext2261
	St. Anthony Central Hospital
		Eduardo Pajon, MD	Ph:  303-399-8020ext2261
	St. Joseph Hospital
		Eduardo Pajon, MD	Ph:  303-399-8020ext2261
	Englewood
	Swedish Medical Center
		Eduardo Pajon, MD	Ph:  303-399-8020ext2261
	Grand Junction
	St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center
		Eduardo Pajon, MD	Ph:  303-399-8020ext2261
	Greeley
	North Colorado Medical Center
		Eduardo Pajon, MD	Ph:  303-399-8020ext2261
	Littleton
	Littleton Adventist Hospital
		Eduardo Pajon, MD	Ph:  303-399-8020ext2261
	Lone Tree
	Sky Ridge Medical Center
		Eduardo Pajon, MD	Ph:  303-399-8020ext2261
	Longmont
	Hope Cancer Care Center at Longmont United Hospital
		Eduardo Pajon, MD	Ph:  303-399-8020ext2261
	Loveland
	McKee Medical Center
		Eduardo Pajon, MD	Ph:  303-399-8020ext2261
	Parker
	Parker Adventist Hospital
		Eduardo Pajon, MD	Ph:  303-399-8020ext2261
	Pueblo
	St. Mary - Corwin Regional Medical Center
		Eduardo Pajon, MD	Ph:  303-399-8020ext2261
	Thornton
	North Suburban Medical Center
		Eduardo Pajon, MD	Ph:  303-399-8020ext2261
	Wheat Ridge
	Exempla Lutheran Medical Center
		Clinical Trials Office - Exempla Lutheran Medical Center	Ph:  303-403-3605
Connecticut
	Hartford
	Helen and Harry Gray Cancer Center at Hartford Hospital
		Clinical Trials Office - Helen and Harry Gray Cancer Center	Ph:  860-545-5363
	Norwich
	Eastern Connecticut Hematology and Oncology Associates
		Dennis Slater, MD	Ph:  860-886-8362
Delaware
	Lewes
	Tunnell Cancer Center at Beebe Medical Center
		Clinical Trials Office - Tunnell Cancer Center	Ph:  302-645-3171
	Newark
	CCOP - Christiana Care Health Services
		Clinical Trial Office - CCOP - Christiana Care Health Services	Ph:  302-623-4450
District of Columbia
	Washington
	Sibley Memorial Hospital
		Bruce Kressel, MD, FACP	Ph:  202-293-5382
Florida
	Fort Lauderdale
	Michael and Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital
		Clinical Trials Office - Michael and Dianne Bienes Comprehensive Cancer Center	Ph:  954-776-3239
	Jupiter
	Ella Milbank Foshay Cancer Center at Jupiter Medical Center
		Clinical Trials Office - Ella Milbank Foshay Cancer Center	Ph:  561-745-5768
	Miami Beach
	CCOP - Mount Sinai Medical Center
		Michael Schwartz, MD	Ph:  305-535-3310
Georgia
	Albany
	Phoebe Cancer Center at Phoebe Putney Memorial Hospital
		Clinical Trials Office - Phoebe Cancer Center	Ph:  229-312-2251
	Macon
	Medical Center of Central Georgia
		Frederick Schnell, MD, FACP	Ph:  478-743-7068
	Savannah
	Nancy N. and J. C. Lewis Cancer and Research Pavilion at St. Joseph's/Candler
		O. George Negrea, MD	Ph:  912-692-2000
Illinois
	Chicago
	Creticos Cancer Center at Advocate Illinois Masonic Medical Center
		Clinical Trials Office - Creticos Cancer Center at Advocate Illinois Masonic Medical Center	Ph:  773-296-5360
	Hematology and Oncology Associates
		Clinical Trails Office - Hematology and Oncology Associates	Ph:  312-695-1301
	John H. Stroger, Jr. Hospital of Cook County
		Paul Rubinstein	Ph:  312-864-3200
	Resurrection Medical Center
		Christopher Rose, MD	Ph:  847-965-3200
	Robert H. Lurie Comprehensive Cancer Center at Northwestern University
		Clinical Trials Office - Robert H. Lurie Comprehensive Cancer Center at Northwestern University	Ph:  312-695-1301
			Email: cancer@northwestern.edu
	University of Chicago Cancer Research Center
		Clinical Trials Office - University of Chicago Cancer Research Center	Ph:  773-834-7424
	University of Illinois Cancer Center
		Clinical Trial Office - University of Illinois Cancer Center	Ph:  312-355-3046
	Decatur
	Decatur Memorial Hospital Cancer Care Institute
		Clinical Trials Office - Decatur Memorial Hospital Cancer Care Institute	Ph:  217-876-4750
	Highland Park
	Kellogg Cancer Care Center
		Jane Winter, MD	Ph:  312-695-4538
	Kankakee
	Provena St. Mary's Regional Cancer Center - Kankakee
		Jane Winter, MD	Ph:  312-695-4538
	Libertyville
	North Shore Oncology and Hematology Associates, Limited - Libertyville
		Jane Winter, MD	Ph:  312-695-4538
	Maywood
	Cardinal Bernardin Cancer Center at Loyola University Medical Center
		Clinical Trials Office - Cardinal Bernardin Cancer Center	Ph:  708-226-4357
	Naperville
	Edward Hospital Cancer Center
		Clinical Trials Office - Edward Hospital Cancer Center	Ph:  630-646-6075
	Hematology Oncology Consultants - Naperville
		Fariborze Barhamand, MD	Ph:  630-369-1501
	Niles
	Cancer Care and Hematology Specialists of Chicagoland - Niles
		Jane Winter, MD	Ph:  312-695-4538
	Skokie
	Hematology Oncology Associates - Skokie
		Jane Winter, MD	Ph:  312-695-4538
Indiana
	Elkhart
	Elkhart Clinic, LLC
		Rafat Ansari, MD, FACP	Ph:  574-234-5123
	Elkhart General Hospital
		Rafat Ansari, MD, FACP	Ph:  574-234-5123
	Michiana Hematology-Oncology, PC - Elkhart
		Rafat Ansari, MD, FACP	Ph:  574-234-5123
	Fort Wayne
	Fort Wayne Medical Oncology and Hematology
		Sreenivasa Nattam, MD	Ph:  260-484-8830
	Kokomo
	Howard Community Hospital
		Rafat Ansari, MD, FACP	Ph:  574-234-5123
	La Porte
	Center for Cancer Therapy at LaPorte Hospital and Health Services
		Rafat Ansari, MD, FACP	Ph:  574-234-5123
	Mishawaka
	Michiana Hematology-Oncology, PC - South Bend
		Rafat Ansari, MD, FACP	Ph:  574-234-5123
	Saint Joseph Regional Medical Center
		Rafat Ansari, MD, FACP	Ph:  574-234-5123
	Plymouth
	Michiana Hematology Oncology PC - Plymouth
		Rafat Ansari, MD, FACP	Ph:  574-234-5123
	South Bend
	CCOP - Northern Indiana CR Consortium
		Rafat Ansari, MD, FACP	Ph:  574-234-5123
	Memorial Hospital of South Bend
		Clinical Trials Office - Memorial Hospital of South Bend	Ph:  800-284-7370
	Michiana Hematology-Oncology, PC - South Bend
		Rafat Ansari, MD, FACP	Ph:  574-234-5123
	Westville
	Michiana Hematology Oncology PC - La Porte
		Rafat Ansari, MD, FACP	Ph:  574-234-5123
Iowa
	Cedar Rapids
	Cedar Rapids Oncology Associates
		Clinical Trials Office - Cedar Rapids Oncology Associates	Ph:  319-363-2690
	Mercy Regional Cancer Center at Mercy Medical Center
		Deborah Wilbur	Ph:  319-398-6011
	Sioux City
	Mercy Medical Center - Sioux City
		Donald Wender, MD, PhD	Ph:  712-252-0088
	Siouxland Hematology-Oncology Associates, LLP
		Donald Wender, MD, PhD	Ph:  712-252-0088
	St. Luke's Regional Medical Center
		Donald Wender, MD, PhD	Ph:  712-252-0088
Kansas
	Chanute
	Cancer Center of Kansas, PA - Chanute
		Shaker Dakhil, MD, FACP	Ph:  316-262-4467
	Dodge City
	Cancer Center of Kansas, PA - Dodge City
		Shaker Dakhil, MD, FACP	Ph:  316-262-4467
	El Dorado
	Cancer Center of Kansas, PA - El Dorado
		Shaker Dakhil, MD, FACP	Ph:  316-262-4467
	Fort Scott
	Cancer Center of Kansas - Fort Scott
		Shaker Dakhil, MD, FACP	Ph:  316-262-4467
	Independence
	Cancer Center of Kansas-Independence
		Shaker Dakhil, MD, FACP	Ph:  316-262-4467
	Kingman
	Cancer Center of Kansas, PA - Kingman
		Shaker Dakhil, MD, FACP	Ph:  316-262-4467
	Lawrence
	Lawrence Memorial Hospital
		Shaker Dakhil, MD, FACP	Ph:  316-262-4467
	Liberal
	Cancer Center of Kansas, PA - Liberal
		Shaker Dakhil, MD, FACP	Ph:  316-262-4467
	Newton
	Cancer Center of Kansas, PA - Newton
		Shaker Dakhil, MD, FACP	Ph:  316-262-4467
	Parsons
	Cancer Center of Kansas, PA - Parsons
		Shaker Dakhil, MD, FACP	Ph:  316-262-4467
	Pratt
	Cancer Center of Kansas, PA - Pratt
		Shaker Dakhil, MD, FACP	Ph:  316-262-4467
	Salina
	Cancer Center of Kansas, PA - Salina
		Shaker Dakhil, MD, FACP	Ph:  316-262-4467
	Topeka
	Cotton-O'Neil Cancer Center
		Clinical Trials Office - Cotton-O'Neil Cancer Center	Ph:  785-270-4963
	Wellington
	Cancer Center of Kansas, PA - Wellington
		Shaker Dakhil, MD, FACP	Ph:  316-262-4467
	Wichita
	Associates in Womens Health, PA - North Review
		Shaker Dakhil, MD, FACP	Ph:  316-262-4467
	Cancer Center of Kansas, PA - Wichita
		Shaker Dakhil, MD, FACP	Ph:  316-262-4467
	Cancer Center of Kansas, PA - Medical Arts Tower
		Shaker Dakhil, MD, FACP	Ph:  316-262-4467
	CCOP - Wichita
		Shaker Dakhil, MD, FACP	Ph:  316-262-4467
	Via Christi Cancer Center at Via Christi Regional Medical Center
		Shaker Dakhil, MD, FACP	Ph:  316-262-4467
	Winfield
	Cancer Center of Kansas, PA - Winfield
		Shaker Dakhil, MD, FACP	Ph:  316-262-4467
Louisiana
	Baton Rouge
	Ochsner Health Center - Bluebonnet
		Charles Wendling, Jr.	Ph:  225-761-5200
	Covington
	Ochsner Health Center - Covington
		Charles Wendling, Jr.	Ph:  985-875-2828 866-624-7637
	New Orleans
	CCOP - Ochsner
		Charles Wendling, Jr.	Ph:  504-842-3910
	Ochsner Cancer Institute at Ochsner Clinic Foundation
		Charles Wendling, Jr.	Ph:  504-842-4360 888-624-7637
Maryland
	Baltimore
	Alvin and Lois Lapidus Cancer Institute at Sinai Hospital
		Roberto Martinez	Ph:  410-601-4734
	Greenebaum Cancer Center at University of Maryland Medical Center
		Clinical Trials Office - Greenebaum Cancer Center at University of Maryladn Medical Center	Ph:  800-888-8823
	Bethesda
	National Naval Medical Center
		Jeremy Perkins	Ph:  301-295-5706
	NIH - Warren Grant Magnuson Clinical Center
		Clinical Trials Office - NIH - Warren Grant Magnuson Clinical Center	Ph:  800-411-1222
	Elkton MD
	Union Hospital of Cecil County
		Stephen Grubbs, MD	Ph:  302-366-1200
	Rockville
	Associates in Oncology and Hematology - Medical Center Drive
		Paul Thambi	Ph:  301-424-6231
Massachusetts
	Boston
	Beth Israel Deaconess Medical Center
		Clinical Trials Office - Beth Israel Deaconess Medical Center	Ph:  617-667-9925
	Dana-Farber/Brigham and Women's Cancer Center
		Clinical Trials Office	Ph:  617-724-5200
	Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
		Jeremy Abramson	Ph:  617-632-3474 866-790-4500
	Massachusetts General Hospital
		Clinical Trials Office - Massachusetts General Hospital	Ph:  877-726-5130
Michigan
	Escanaba
	Green Bay Oncology, Limited - Escanaba
		Thomas Saphner, MD, FACP	Ph:  920-884-3135
	Iron Mountain
	Dickinson County Healthcare System
		Thomas Saphner, MD, FACP	Ph:  920-884-3135
	Kalamazoo
	Borgess Medical Center
		Raymond Lord, MD	Ph:  269-373-7458
	Bronson Methodist Hospital
		Raymond Lord, MD	Ph:  269-373-7458
	West Michigan Cancer Center
		Clinical Trials Office - West Michigan Cancer Center	Ph:  269-373-7458
	Niles
	Michiana Hematology Oncology PC - Niles
		Rafat Ansari, MD, FACP	Ph:  574-234-5123
	Saint Joseph
	Lakeside Cancer Specialists, PLLC
		Rafat Ansari, MD, FACP	Ph:  574-234-5123
	Southfield
	Providence Cancer Institute at Providence Hospital - Southfield Campus
		Anibal Drelichman, MD, MPH, FACP	Ph:  313-552-0620
	St. Joseph
	Lakeland Regional Cancer Care Center - St. Joseph
		Rafat Ansari, MD, FACP	Ph:  574-234-5123
Mississippi
	Jackson
	University of Mississippi Cancer Clinic
		Vincent Herrin	Ph:  601-984-5590
Missouri
	Columbia
	Ellis Fischel Cancer Center at University of Missouri - Columbia
		Clinical Trial Office - Ellis Fischel Cancer Center	Ph:  573-882-7440
	Saint Louis
	Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
		Nancy Bartlett, MD	Ph:  314-362-5654
Montana
	Billings
	Billings Clinic - Downtown
		Clinical Trials Office - Billings Clinic - Downtown	Ph:  800-996-2663
			Email: research@billingsclinic.org
	CCOP - Montana Cancer Consortium
		Benjamin Marchello, MD	Ph:  406-238-6290
	Hematology-Oncology Centers of the Northern Rockies - Billings
		Benjamin Marchello, MD	Ph:  406-238-6290
	St. Vincent Healthcare Cancer Care Services
		Benjamin Marchello, MD	Ph:  406-238-6290
	Bozeman
	Bozeman Deaconess Cancer Center
		Benjamin Marchello, MD	Ph:  406-238-6290
	Butte
	St. James Healthcare Cancer Care
		Benjamin Marchello, MD	Ph:  406-238-6290
	Great Falls
	Big Sky Oncology
		Clinical Trial Office - Big Sky Oncology	Ph:  406-731-8217
	Great Falls Clinic - Main Facility
		Benjamin Marchello, MD	Ph:  406-238-6290
	Sletten Cancer Institute at Benefis Healthcare
		Grant Harrer, MD, FACP, CCTI	Ph:  406-731-8100
	Havre
	Northern Montana Hospital
		Benjamin Marchello, MD	Ph:  406-238-6290
	Helena
	St. Peter's Hospital
		Benjamin Marchello, MD	Ph:  406-238-6290
	Kalispell
	Glacier Oncology, PLLC
		Benjamin Marchello, MD	Ph:  406-238-6290
	Kalispell Medical Oncology at KRMC
		Benjamin Marchello, MD	Ph:  406-238-6290
	Kalispell Regional Medical Center
		Benjamin Marchello, MD	Ph:  406-238-6290
	Missoula
	Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
		Clinical Trials Office - Montana Cancer Center at St. Patrick Hospital and Health Sciences Center	Ph:  406-329-7029
Nevada
	Las Vegas
	CCOP - Nevada Cancer Research Foundation
		John Ellerton, MD, CM	Ph:  702-384-0013
	University Medical Center of Southern Nevada
		John Ellerton, MD, CM	Ph:  702-384-0013
New Hampshire
	Concord
	New Hampshire Oncology - Hematology, PA at Payson Center for Cancer Care
		Douglas Weckstein, MD	Ph:  603-622-6484
	Hooksett
	New Hampshire Oncology - Hematology, PA - Hooksett
		Douglas Weckstein, MD	Ph:  603-622-6484
	Manchester
	Elliot Regional Cancer Center at Elliot Hospital
		Douglas Weckstein, MD	Ph:  603-622-6484
New Jersey
	East Orange
	Veterans Affairs Medical Center - East Orange
		Basil Kasimis, MD, DSc	Ph:  973-395-7809
	Hackensack
	CCOP - Northern New Jersey
		Andre Goy	Ph:  201-996-5834
	Newark
	UMDNJ University Hospital
		Lillian Pliner, MD, FACP	Ph:  973-972-6257
	Paterson
	St. Joseph's Hospital and Medical Center
		Michael Maroules	Ph:  973-754-2405
	Voorhees
	Cancer Institute of New Jersey at Cooper - Voorhees
		Clinical Trials Office - Cancer Institute of New Jersey at Cooper University Hospital - Voorhees	Ph:  856-325-6757
New Mexico
	Albuquerque
	Hematology Oncology Associates, PC
		Dulcinea Quintana	Ph:  505-938-5858
	Lovelace Medical Center - Downtown
		Dulcinea Quintana	Ph:  505-727-8000
	University of New Mexico Cancer Center
		Clinical Trials Office - University of New Mexico Cancer Center	Ph:  505-272-6972
	Las Cruces
	University of New Mexico Cancer Center - South
		Dulcinea Quintana	Ph:  505-521-1554
	Santa Fe
	New Mexico Cancer Care Associates
		Clinical Trials Office - New Mexico Cancer Care Associates	Ph:  505-955-7910
New York
	Bronx
	Albert Einstein Cancer Center at Albert Einstein College of Medicine
		Clinical Trials Office - Albert Einstein Cancer Center at Albert Einstein College of Medicine	Ph:  718-904-2730
			Email: aecc@aecom.yu.edu
	Buffalo
	Roswell Park Cancer Institute
		Clinical Trials Office - Roswell Park Cancer Institute	Ph:  877-275-7724
	Glens Falls
	Charles R. Wood Cancer Center at Glens Falls Hospital
		Clinical Trials Office - Charles R. Wood Cancer Center at Glens Falls Hospital	Ph:  518-926-6700
	New York
	New York Weill Cornell Cancer Center at Cornell University
		Clinical Trials Office - New York Weill Cornell Cancer Center at Cornell University	Ph:  212-746-1848
	NYU Cancer Institute at New York University Medical Center
		Bruce Raphael, MD	Ph:  212-731-5185
	Rochester
	James P. Wilmot Cancer Center at University of Rochester Medical Center
		Jonathan Friedberg	Ph:  585-275-5345
	Syracuse
	SUNY Upstate Medical University Hospital
		Clinical Trials Office - SUNY Upstate Medical University Hospital	Ph:  315-464-5476
North Carolina
	Charlotte
	Presbyterian Cancer Center at Presbyterian Hospital
		Clinical Trials Office - Presbyterian Cancer Center at Presbyterian Hospital	Ph:  704-384-5369
	Goldsboro
	Wayne Memorial Hospital, Incorporated
		James Atkins, MD	Ph:  919-580-0000
	Kinston
	Kinston Medical Specialists
		Peter Watson, MD	Ph:  252-559-2200ext.201
	Winston-Salem
	Wake Forest University Comprehensive Cancer Center
		Clinical Trials Office - Wake Forest University Comprehensive Cancer Center	Ph:  336-713-6771
Ohio
	Akron
	McDowell Cancer Center at Akron General Medical Center
		Esther Rehmus, MD	Ph:  330-344-6505
	Canton
	Mercy Cancer Center at Mercy Medical Center
		Mitchell Haut, MD	Ph:  330-453-9993
	Cleveland
	Case Comprehensive Cancer Center
		Clinical Trials Office - Case Comprehensive Cancer Center	Ph:  800-641-2422
	Lima
	St. Rita's Medical Center
		Clinical Trials Office - St. Rita's Medical Center	Ph:  419-226-9617
Pennsylvania
	Danville
	Geisinger Cancer Institute at Geisinger Health
		Clinical Trials Office - Geisinger Cancer Institute	Ph:  570-271-5251
	Hazleton
	Geisinger Hazleton Cancer Center
		Edward Gorak, II	Ph:  570-459-2901
	Hershey
	Penn State Hershey Cancer Institute at Milton S. Hershey Medical Center
		Clinical Trials Office - Penn State Hershey Cancer Institute at Milton S. Hershey Medical Center	Ph:  717-531-3779
			Email: CTO@hmc.psu.edu
	Lewistown
	Lewistown Hospital
		Elliot Epner, MD, PhD	Ph:  503-494-1551
	Pittsburgh
	Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital
		John Lister	Ph:  412-578-5000
	Scranton
	Hematology and Oncology Associates of Northeastern Pennsylvania
		Martin Hyzinski, MD	Ph:  570-558-3020
	Mercy Hospital Cancer Center - Scranton
		Martin Hyzinski, MD	Ph:  570-558-3020
	State College
	Geisinger Medical Group - Scenery Park
		Edward Gorak, II	Ph:  814-231-4560
	Mount Nittany Medical Center
		Elliot Epner, MD, PhD	Ph:  503-494-1551
	Wilkes-Barre
	Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center
		Clinical Trials Office - Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center	Ph:  570-271-5251
Rhode Island
	Pawtucket
	Memorial Hospital of Rhode Island
		Anthony Thomas, DO	Ph:  401-729-2700
South Carolina
	Charleston
	Hollings Cancer Center at Medical University of South Carolina
		Clinical Trials Office - Hollings Cancer Center at Medical University of South Carolina	Ph:  843-792-9321
Tennessee
	Nashville
	Vanderbilt-Ingram Cancer Center
		Clinical Trials Office - Vanderbilt-Ingram Cancer Center	Ph:  800-811-8480
Texas
	Amarillo
	Harrington Cancer Center
		Clinical Trials Officec - Harrington Cancer Center	Ph:  806-359-4673
			Email: ryokubaitis@harringtoncc.org
Vermont
	Berlin
	Mountainview Medical
		Barbara Grant, MD	Ph:  802-847-8400
	Burlington
	Fletcher Allen Health Care - University Health Center Campus
		Clinical Trials Office - Fletcher Allen Health Care	Ph:  802-656-8990
Virginia
	Richmond
	Virginia Commonwealth University Massey Cancer Center
		Clinical Trials Office -Virginia Commonwealth University Massey Cancer Center	Ph:  804-628-1939
Washington
	Anacortes
	Island Hospital Cancer Care Center at Island Hospital
		Saul Rivkin, MD	Ph:  206-386-2441
	Bellingham
	St. Joseph Cancer Center
		Saul Rivkin, MD	Ph:  206-386-2441
	Bremerton
	Olympic Hematology and Oncology
		Saul Rivkin, MD	Ph:  206-386-2441
	Burien
	Highline Medical Center Cancer Center
		Saul Rivkin, MD	Ph:  206-386-2441
	Centralia
	Providence Centralia Hospital
		Clinical Trials Office - Providence Centralia Hospital	Ph:  360-493-4300
	Federal Way
	St. Francis Hospital
		Yoshio Inoue	Ph:  253-944-7997
	Kennewick
	Columbia Basin Hematology
		Saul Rivkin, MD	Ph:  206-386-2441
	Kirkland
	Cascade Cancer Center at Evergreen Hospital Medical Center
		Craig Nichols, MD	Ph:  503-494-6346
	Mount Vernon
	Skagit Valley Hospital Cancer Care Center
		Saul Rivkin, MD	Ph:  206-386-2441
	Olympia
	Providence St. Peter Hospital Regional Cancer Center
		Yoshio Inoue	Ph:  360-493-7514
	Poulsbo
	Harrison Poulsbo Hematology and Onocology
		Saul Rivkin, MD	Ph:  206-386-2441
	Puyallup
	Good Samaritan Cancer Center
		Yoshio Inoue	Ph:  253-697-4000
	Seattle
	CCOP - Virginia Mason Research Center
		Craig Nichols, MD	Ph:  503-494-6346
	Group Health Central Hospital
		Clinical Trials Office - Group Health Central Hospital	Ph:  206-287-2900
	Minor and James Medical, PLLC
		Saul Rivkin, MD	Ph:  206-386-2441
	Pacific Medical Center
		Craig Nichols, MD	Ph:  503-494-6346
	Swedish Cancer Institute at Swedish Medical Center - First Hill Campus
		Saul Rivkin, MD	Ph:  206-386-2441
	University Cancer Center at University of Washington Medical Center
		Saul Rivkin, MD	Ph:  206-386-2441
	Virginia Mason Medical Center
		Craig Nichols, MD	Ph:  503-494-6346
	Sedro-Woolley
	North Puget Oncology at United General Hospital
		Saul Rivkin, MD	Ph:  206-386-2441
	Spokane
	Cancer Care Northwest - Spokane South
		Clinical Trials Office - Cancer Care Northwest - Spokane South	Ph:  509-228-1083
	Evergreen Hematology and Oncology, PS
		Saul Rivkin, MD	Ph:  206-386-2441
	Tacoma
	Allenmore Hospital
		Yoshio Inoue	Ph:  253-459-6446
	CCOP - Northwest
		Yoshio Inoue	Ph:  253-403-1461
	Franciscan Cancer Center at St. Joseph Medical Center
		Clinical Trials Office - Franciscan Cancer Center	Ph:  253-426-6914
	Madigan Army Medical Center - Tacoma
		Anthony Fadell	Ph:  206-968-1110
	MultiCare Regional Cancer Center at Tacoma General Hospital
		Clinical Trials Office - MultiCare Regional Cancer Center	Ph:  253-403-3229
	St. Clare Hospital
		Yoshio Inoue	Ph:  253-588-1711
	Wenatchee
	Wenatchee Valley Medical Center
		Clinical Trials Office - Wenatchee Valley Medical Center	Ph:  509-665-5800
West Virginia
	Morgantown
	Mary Babb Randolph Cancer Center at West Virginia University Hospitals
		Sayed Hamadani	Ph:  304-293-4500 877-427-2894
Wisconsin
	Chippewa Falls
	Marshfield Clinic - Chippewa Center
		Ali Bseiso, MD	Ph:  715-387-5416
	Eau Claire
	Marshfield Clinic Cancer Care at Regional Cancer Center
		Ali Bseiso, MD	Ph:  715-387-5416
	Green Bay
	Green Bay Oncology, Limited at St. Mary's Hospital
		Thomas Saphner, MD, FACP	Ph:  920-884-3135
	Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
		Thomas Saphner, MD, FACP	Ph:  920-884-3135
	St. Mary's Hospital Medical Center - Green Bay
		Thomas Saphner, MD, FACP	Ph:  920-884-3135
	St. Vincent Hospital Regional Cancer Center
		Clinical Trials Office - St. Vincent Hospital Regional Cancer Center	Ph:  920-433-8889
	Madison
	University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
		Clinical Trials Office - University of Wisconsin Paul P. Carbone Comprehensive Cancer Center	Ph:  608-262-5223
	Manitowoc
	Holy Family Memorial Medical Center Cancer Care Center
		Clinical Trials Office - Holy Family Memorial Medical Center Cancer Care Center	Ph:  920-320-2749
	Marinette
	Bay Area Cancer Care Center at Bay Area Medical Center
		Thomas Saphner, MD, FACP	Ph:  920-884-3135
	Marshfield
	Marshfield Clinic - Marshfield Center
		Clinical Trials Office - Marshfield Clinic - Marshfield Center	Ph:  800-782-1581 ext. 94457
	Saint Joseph's Hospital
		Ali Bseiso, MD	Ph:  715-387-5416
	Minocqua
	Marshfield Clinic - Lakeland Center
		Ali Bseiso, MD	Ph:  715-387-5416
	Oconto Falls
	Green Bay Oncology, Limited - Oconto Falls
		Thomas Saphner, MD, FACP	Ph:  920-884-3135
	Rhinelander
	Ministry Medical Group at Saint Mary's Hospital
		Ali Bseiso, MD	Ph:  715-387-5416
	Rice Lake
	Marshfield Clinic - Indianhead Center
		Ali Bseiso, MD	Ph:  715-387-5416
	Sheboygan
	St. Nicholas Hospital
		Thomas Saphner, MD, FACP	Ph:  920-884-3135
	Stevens Point
	Marshfield Clinic at Saint Michael's Hospital
		Ali Bseiso, MD	Ph:  715-387-5416
	Saint Michael's Hospital Cancer Center
		Ali Bseiso, MD	Ph:  715-387-5416
	Sturgeon Bay
	Green Bay Oncology, Limited - Sturgeon Bay
		Thomas Saphner, MD, FACP	Ph:  920-884-3135
	Weston
	Diagnostic and Treatment Center
		Ali Bseiso, MD	Ph:  715-387-5416
	Marshfield Clinic - Weston Center
		Ali Bseiso, MD	Ph:  715-387-5416
	Ministry Saint Clare's Hospital
		Ali Bseiso, MD	Ph:  715-387-5416
	Wisconsin Rapids
	Marshfield Clinic - Wisconsin Rapids Center
		Ali Bseiso, MD	Ph:  715-387-5416
Wyoming
	Sheridan
	Welch Cancer Center at Sheridan Memorial Hospital
		Benjamin Marchello, MD	Ph:  406-238-6290

Related Information

Web site for additional information

Registry Information
Official Title		Phase III Randomized Study of R-CHOP V. Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas
Trial Start Date		2005-05-02
Trial Completion Date		2010-03-29 (estimated)
Registered in ClinicalTrials.gov		NCT00118209
Date Submitted to PDQ		2005-05-06
Information Last Verified		2012-02-08
NCI Grant/Contract Number		CA31946

Back to Top